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Microvesicle particles (MVPs) are subcellular particles that could be 
involved in inter-cellular communication because they carry various 
bioactive substances including cytokines. Previous studies from our lab 
has shown that that the lipid mediator Platelet-activating Factor (1-alkyl-
2-acetyl-glycerophosphocholine; PAF) and ultraviolet B radiation (UVB) 
enhances the release of MVP in various cell types like primary 
keratinocytes, epithelial cell lines, and murine skin. We hypothesized that 
there may be synergistic increases in MVP release after combination of 
treatment of keratinocytes with UVB and PAF agonist (CPAF)/phorbol 
ester (PMA). The combination treatment significantly increases MVP and 
cytokine release at 4 to 8 hours time points. Imipramine, an acid 
sphingomyelinase (aSMase) inhibitor blocks MVP and cytokine release 
which indicates that MVP could be involved in cytokine release. The 
 iv 
 
increased level of TNF-alpha in the supernatant was not present in the 
MVP but surprisingly there was increased level of anti-inflammatory 
cytokine, Interleukin 1- receptor antagonist (IL-1ra) inside MVP after UVB 
treatment than in combination treatment, which could portray potential 
imbalances between pro-inflammatory cytokines and down regulating 
responses in exaggerated condition.  These studies suggest that MVP 
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Chapter 1: Introduction 
 
1.1 Statement of problem 
 
Microvesicle particles (MVPs) are subcellular particles which have been 
suggested to be important mediators in inter-cellular communication. 
They are believed to carry various bioactive molecules like proteins, 
nucleic acids, cytokines, RNAs and many other molecules from parent 
cells to recipient cells through various mechanisms in both normal and 
disease states. MVP are not only important biomarkers in various disease 
states but also can be potentially used for diagnostic and therapeutical 
purposes. Our group has previously found that various environmental 
stressors increases the release of MVPs in skin keratinocytes.  We 
hypothesize that combining these environmental stressors, will lead to 
synergistic increase in MVP release along with cytokine TNF-alpha and 
to determine the relation between cytokines release and MVPs are the 





 1.2. Significance 
 
The significance of this study is that MVPs play important roles in 
transporting various cytokines as they can travel to any parts of the body. 
Thus, blocking these inflammatory cytokines could be new targets for 
treating various diseases. Here our group has implicated Platelet 
Activating Factor agonist and ultraviolet B Radiation in how these 
stressors lead to release of MVPs and cytokines and are these cytokines 
release and MVPs are interconnected to each other, as well as whether 
combinations of these stressors could augment the release of MVPs and 
cytokines. For an example, studies have shown that people with mild 
hypersensitivity reaction when treated with ultraviolent radiation result in 
Tumor necrolysis factor, leading to serious systemic effects 1. These 
studies can provide important and clinically relevant insights in how the 







1.3. Statement of Purpose 
 
The main purpose of this study is divided into two parts. First, we will 
attempt to verify whether combination of two stressors PAF-R agonist and 
UVB will increase the release of MVP along with cytokines. Does 
treatment of human keratinocytes and epidermoid cell lines with CPAF 
and UVB has synergistic effect in release of MVPs and cytokines? Does 
the acid sphingomyelinase inhibitor imipramine block the release of MVPs 
and cytokines? Second, Is the cytokines and MVPs release 
interconnected to each other? Do MVP carry these cytokines and to 






Our hypothesis is that combination of PAF receptor agonist with 
ultraviolet B radiation will lead to an increase in MVP release along with 
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cytokines in comparison with controls and individual treatments in human 
epidermoid cell lines HaCaT and KBP. 
Along with that, we expect that there will be a decrease in the release of 
MVPs and cytokines when treated with acid sphingomyelinase inhibitor 
imipramine. We expect that the exaggerated level of cytokines are 
present in MVP and MVP act as a carrier of these cytokines. 
 
1.5. Research objectives 
 
➢ To determine if the combination of UVB and PAF receptor 
agonist or phorbol ester increases the release of MVPs and 
cytokines in a synergistic manner. 
➢ To determine if the treatment with the aSMase inhibitor 
imipramine blocks the release of MVPs and cytokines. 
➢ To assess if the release of cytokines and MVPs are 
interconnected with each other. Do MVPs carry cytokines 







We made the assumption that different skin keratinocytes and epithelial 
cell lines respond in the same manner as the human system when treated 
with different agents. The murine model used in the experiments respond 
to all the treatments used in the experiment. The gender and age group 
of mice will not affect the results with different treatment groups. 
 
 




 Ultraviolet B Radiation (UVB), an environmental stressor is known to 
cause both local and systemic effects in humans. Since UVB is known to 
penetrate only the epidermal layer of the skin, the mechanism by which it 
causes systemic effects are still unknown. We have previously published 
that UVB induces Microvesicle Particles (MVPs) in dose-dependent 
manner via Platelet Activating Factor Receptor (PAF-R)2. The increase in 
the dose of UVB, there is an increase in the MVP release, but we believe 
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that when we combine two or more stressors like UVB and PAF agonist 
there is synergistic increase in the MVP release even with a low dose of 
UVB. The MVP do carry various proteins, cytokines and nucleic acid, and 
we do believe that these MVP may carry inflammatory cytokines which 
may cause systemic effect though UVB doesn’t penetrate the dermal 
layer of the skin. 
 
2.2. Microvesicle Particles 
 
Microvesicle particles (MVPs; microparticles, microvesicles) are small 
spherical shape vesicles, with a size of 100-1000 nm, which are secreted 
by plasma membrane through outward budding basically by ecto-cytosis 
processes3.  Previously, it was considered as cell debris and was felt not 
to serve any functions. MVP can be shed from almost all kinds of 
eukaryotic cells in an energy dependent manner 3. Although there were 
originally not many studies in this area, increasing interest in the 
biogenesis and contents of MVP has changed the context about these 
extracellular vesicles. MVP have been reported to contain various 
bioactive substances like inflammatory cytokines, lipids, proteins and 
nucleic acids 4.  
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They are also capable of transferring various biological information to the 
target cells by direct fusion or internalization. However the mechanism of 
how MVP transfers the biological content and their contribution in the 
pathophysiology of different diseases are not completely known as yet5.  
 The exact mechanism of release of MVP in keratinocytes is not known 
but there are several reports which has shown the mechanism of release 
of MVP in other cell types. Among different pathways for release of MVP, 
one of them is through the activation of ATP receptor P2X7R. In the 
microglial cells, the activation of inotropic ATP receptor P2X7R induces 
MVP shedding. The activation of AT1P receptor enhances the release of 
ATP from various degenerating cells or the lesion formed through the 
propagation of ATP mediated Ca++ wave in the astrocyctes6.  Another 
known mechanism is through cleavage of Rho Kinase I (ROCK I) by 
Capase 3, during apoptosis that leads to dysregulated activity of ROCK I 
kinase and consequently leads to bleb formation7.  
Most of the studies have reported that MVP regulation were associated 
with ATP dependent P2X7R6,8. The first pathway is through P2X7R 
mediated MVP release, the  phosphatidylserine (PS) exposure at the 
surface of the cell leads to loss of plasma membrane asymmetry and 
there occurs the membrane blebbing. The second pathway is via 
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activation of ATP receptor P2X7R, where acid sphingomyelinase 
(aSMase) enzyme translocates from lysosomal region to the outer 
plasma membrane9. Acid sphingomyelinase enzyme hydrolyze the 
sphingomyelin lipid present in the cell membrane into ceramide and 
phospholipid, causes membrane fluidity and induces membrane 
destability, which facillitate membrane blebbing and MVP shedding10. It 
is also noted that aSMase induced MVP release increased inflammatory 
cytokines in MVP11.  The generation of MVP from plasma membrane 
represent the major process of release of cytokines in the glial cells and 
the blockade of cytokine release from aSMase KO astrocytes is 
confirmatory23. The acid sphingomyelinase enzyme inhibitors such as 
imipramine block the release of MVP and inflammatory cytokines IL-1β in 
the microglial cells6.  
Figure 1. Mechanism involved in MVP shedding mediated by 






The stimulation of P2X7R with BzATP activates p38 MAPK cascade via 
activation of src kinase-mediated phosphorylation. The stimulation of P-
p38 triggers two different pathway along with plasma membrane pore 
formation (a) and transfer of aSMase from lysosomal region to outer 
plasma membrane (b) the aSMase enzyme alters the rigidity of plasma 
membrane leading to MVP generation9. 
Relatively little is known regarding MVP derived from keratinocytes.  Yet, 
it has been reported that MVP derived from other cell types contains 
various cytokines like TNF-alpha from alveolar macrophages12 and 
endothelial cells 13. We hypothesized that MVP derived from 
keratinocytes could contain several cytokines and involved in 
pathogenesis of various local and systemic effect. 
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Our lab has previously found that treating keratinocytes cell line with UVB 
and PAF agonist (CPAF), HaCaT cells results in the release of MVP. And 
importantly UVB irradiated in human epithelial KB cells transduced with 
PAF receptor postive and negative cell lines, only PAF receptor positive 
cell lines results in release of MVP. This proves that PAF signaling is 
important in MVP release14. However the combination of UVB and PAF-
agonist will lead to exaggerated release of MVP in human keratinocytes 
and mice model has not yet been studied. In this study, the combination 
of UVB and CPAF in the production of MVP will be analyzed. From 
different studies it is known that MVP carries various pro-inflammatory 
cytokines like IL-1β, tumor necrosis factor (TNF-alpha) and Interleukin-6 
(IL-6) increase the tumor growth and other complications15. In this study 
we will be addressing the correlation between MVP release and 
cytokines. We hypothesize that MVP could be a potential carrier for 
cytokines and could play a vital role in pathogenesis of several diseases. 
Our laboratory has described a hypothetical model of UVB induced MVP 
release.  When a keratinocyte is irradiated with UVB, it stimulates PAF-R 
and PAF agonist via reactive oxygen species. The created PAF agonists 
acts on PAF-R and releases the aSMase enzyme from lysosomal 
compartment to the plasma membrane. The aSMase enzyme breaks the 
sphingomyelin lipids into ceramide and phosphocholine. The release of 
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ceramide in the plasma membrane tiggers MVP release. The aSMase 










Figure 2. Hypothetical model of UVB induced MVP release in 
human keratinocytes2,4. 
 
2.3 Ultraviolet B Radiation 
 
Ultraviolet Radiation (UV) is one of the main important environmental 
factors that causes different complications like skin cancers, cutaneous 
inflammation and both local and systemic immunosuppression16,17. The 







They are UVA (320-400nm), UVB (290-320nm) and UVC (100-290nm)18. 
Only 5% of UVB and approximately 95% of UVA reaches the earth 
surface. Though UVA is more prevalent than UVB, it is of lower energy.  
UVA penetrates the deeper layer of skin and reaches the dermal layer18.   
UVB which only reaches the epidermal layer of skin and thus cannot 
penetrate the inner layer of skin (dermal layer) but exposure of UVB to 
the skin has profound systemic effects19. When UVB is exposed to 
epidermal layer of skin, the keratinocytes, releases many cytokines like 
tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-1, IL-8, IL-6, IL-
10, and, transforming growth factor-alpha (TGF-α), granulocyte colony-
stimulating factor (G-CSF), interferon gamma (INF-γ), macrophage-CSF, 
platelet derived growth factor (PDGF), TGF-β, macrophage-CSF which 
are involved in UVB induced inflammatory responses18,19. The enhanced 
alarmin high mobility group box 1 (HMGB1) has profound effect in 
generation of inflammatory responses in keratinocytes due to UVB20.   
Various bioactive lipids, such as prostaglandin E2 and PAF are stimulated 
by UVB radiation21. In human keratinocytes, UVB induces various protein 
cytokines along with lipid mediator Platelet Activating Factor (1-O-alkyl-2 
acetyl glycerophosphocholine, PAF)21. PAF is a very potent activator of 
various cell types like monocytes, mast cells, leukocytes, acting via a G-
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protein coupled receptor. It plays a pivotal role in different signaling 
pathways and is involved in pathological condition like oxidative stress 
and bacterial infection22.  
As mentioned earlier, UVB-induced MVP release is dependent on PAF-
R2,4. UVB and PAF activation leads to generation of several cytokines like 
IL-1β, IL-6, IL-8, IL-10 and TNF-alpha18,19,26,27. In particular, combination 
of both UVB and PAF-R agonist leads to synergistic increase in the 
cytokine TNF-alpha release20, we are interested to learn if these 
combination studies leads to exaggerated level of MVP and cytokines in 
human keratinocytes. And the high level of TNF-alpha secreted by the 
stimulated cells are carried by the MVP, a novel mechanism involved in 
inter-cellular communication5.  
 
2.4 Platelet Activating Factor Receptor (PAF-R) 
 
Platelet Activating Factor (1-alkyl-2-acetyl-glycerophosphocholine; PAF) 
is an important imflammatory phospholipid and is activated via G-protein 
coupled receptor16. It is present in various innate immune system along 
with keratinocytes23. PAF plays role in platelet aggregation, inflammation 
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and allergic reactions. Human keratinocytes (HaCaT) was found with 
endogeneous PAF receptor24. 
The activation of PAF receptor is triggered by various pro-oxidative 
stressors like chemotherapeutic agents, cigarette smoke, aromatic 
hydrocarbon and ultraviolet B Radiation. These stressors induces ROS 
and acts on glycerophosphocholines (GPC) to produce PAF agonist, 
oxidized GPC (ox-GPC),that activates the PAF- receptor25. The PAF is 
also activated by carbamyl-platelet-activating factor (1-hexadecyl-2-N-
methylcarbamyl-glycero-3-phosphocholine; CPAF), a functional analog 
of PAF, which is non metabolizable and can be used as stable PAF 
agonist in in-vitro, ex vivo study and in-vivo studies21. 
UVB irradiation in human skin can increase the formation of PAF/ox-
GPC21. UVB induces the release of reactive oxygen species (ROS), ROS 
activates PAF-R. Activation of epidermal PAF-R result increased 
synthesis of PAF, eicosanoids, COX-2 and cytokines like IL-6 and IL-8, 
TNF-α21. Studies on HaCaT cells and KB cells transduced with PAF-R 
showed that activation of PAF-R receptor results increased level of 
cytokines (IL-6/IL-8) and cyclooxygenase (COX-2) which are known to 
induce inflammatory responses26,27. This results in activation of several 
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signaling pathways, including protein tyrosine kinases, phospholipases 
and phosphatidylinositol-3-kinase26,27. 
From previous studies it is known that PAF is synthesized by UVB 
radiation. Either, PAF-R or UVB produces tumor necrosis factor (TNF-α), 
a mediator of cutaneous inflammation13,14,21. Previous studies has shown 
that activation of PAF-R along with combination of UVB results in 
synergistic TNF-alpha production in human PAF-R-expressing KB cells 
and as well as murine skin20. This finding could have possible clinical 
importance in treatment of photosensitive disorders20. 
Though UVB irradiation is only absorbed in the epidermal layer, it can 
cause systemic effects.  Thus, mediators like extracellular particles which 
can circulate in the microenvironment could potentially transfer cytokines 
and PAF agonists from skin epidermal layer to the whole body has known 









Cytokines are glycoproteins produced by many immune cells like 
neutrophils, monocytes, macrophages, T-cells and B-cells to regulate 
immune responses  and involved in regulation of immune responses16. 
They are involved in various physiological functions and inflammatory 
responses29. They are sub-divided into various classes like Interleukins 
(ILs) of which 35 has been described30, tumor necrosis factors (TNFs), 
interferons (IFNs), transforming growth factors (TGFs), colony-
stimulating factors (CSFs), and various chemokines16,28. It has been 
found that in atherosclerosis, pro-inflammatory cytokines and Th-1 
related cytokines enhance the progression and development of several 
diseases while on the other side anti-inflammatory and regulatory T cell 
related cytokines induces anti-atherogenic activities29. In this project we 
emphasized on Tumor necrosis factors (TNF-alpha) and 27 other 
cytokines level were analyzed in the MVP. They are: Interleukins ( IL-1β, 
IL-1ra, IL-2, IL-4, IL-6, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17), FGF 
basic, Eotaxin, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1(MCAF), MIP-1α, 




2.5.1 Tumor Necrosis Factor (TNF-alpha) 
 
TNF-alpha is a pro-inflammatory cytokines which is involved in regulating 
inflammatory responses31. It is involved in cell proliferation, differentiation 
and cell death32. It is released by monocytes, macrophages, T-cells, B 
cells and fibroblast31,33. It is potent stimulator of autocrine and paracrine 
which enhances release of inflammatory cytokines like IL-1, IL-6, IL-8 an 
granulocyte-monocyte colony stimulating factor31,33. TNF-alpha is known 
to induce various inflammatory responses like atherosclerosis, 
rheumatoid arthritis, cancers and toxic epidermal necrolysis1. TNF-alpha 
exerts its biological functions through activation of different pathways like 
nuclear factor KB (NF-KB) and c-Jun N-terminal kinase (JNK)32. These 
signaling pathways are involved in cancer biology with main emphasis on 
cancer biology and carcinogenesis32. 
Previous studies have found that higher level of TNF-alpha was found in 
the skin lesions of psoriatic patients compared to normal skin34. Reactive 
oxygen species from various environmental stressors like UVB, dietary 
toxicity and drug metabolites enhances the level of TNF-alpha in primary 
keratinocytes34. The induction of TNF-alpha from keratinocytes is mainly 
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associated with UVA or UVB irradiation leading to photodamage and 
photoaging35. The combination of UVB with other cytokines like IL-1α 
upregulates the expression of mRNA level of TNF-alpha in human 
keratinocytes35.  
Primary keratinocytes are known to generate and release a variety of 
soluble mediators such as IL-1β, IL-6, IL-8, TNF-alpha and other 
transforming growth factors. These cytokines mediate local inflammatory 
responses in the epidermis and also they can enter the circulation and 
cause systemic effects36.  
In our studies, the primary focus is to study the role of MVP in the level of 
TNF-alpha generated via ROS induced by UVB in human keratinocytes. 
The high level of TNF-alpha in the supernatant from the stimulated cells, 
not only cause local effect in epidermal layer but also can induce systemic 
effect via circulation in the body system.  
 
2.5.2 Interleukin 1 Beta 
 
Interleukin 1 Beta (IL-1-beta) is a pro-inflammatory cytokine derived from 
monocytes, macrophages, dendritic cells as well as B-lymphocytes and 
NK cells36. It is one of the most studies cytokines in IL-1 family37. It is 
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important cytokine involved for host defense in injury and infection37. IL-
1β inhibitors are used in the treatment of autoinflammatory skin 
diseases38. 
2.5.3 IL-1 Receptor antagonist 
 
It is also known as Anakinra, which is used to treat autoimmune disorders 
and different types of cancer. It belongs to IL-1 family but do not cause 
inflammatory responses.  IL-1ra completely antagonizes the effect of IL-
1 beta and IL-1 alpha. It has naturally occurring anti-inflammatory effects 
which are unique. Skin keratinocytes, epithelial cells, stromal cells, 
hepatocytes and adipocytes all have been reported to secrete IL-1ra39. 
 
 
2.5.4 Interleukin 2 
 
Interleukin 2 (IL-2) is a cytokine with a very complex signaling pathway, 
secreted from keratinocytes, macrophages, THCs, CTLs. It is mainly 
involved in T cell signaling but also has been implicated in processes 
such as wound healing40. It is involved in T-cell induction and proliferation. 
Absence of IL-2 in murine model was found to be prone to autoimmune 
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disorders40. It is also involved in cellular communication via complex 
receptors. IL-2 is used clinically as immunotherapy in patients with 
infectious diseases and disseminated cancer41.  
2.5.5 Interleukin 4 
 
Interleukin 4 (IL-4) is anti-inflammatory cytokine which helps in down 
regulation of autoimmunity by suppressing of TH1 cells42. IL-4 is mainly 
released by mast cells, eosinophils, basophils and TH2 cells43. This is 
involved in growth and differentiation of CD4+T lymphocytes into TH2 
cells44. 
2.5.6 Interleukin 5 
 
Interleukin 5 (IL-5) is a pro-inflammatory cytokine, expressed in NK, NKT 
cells and eosinophils, and other non-hematopoietic cells45. The signaling 
pathway involved in IL-5 is through activation of JAK/STAT pathway46. IL-






2.5.7 Interleukin 6 
 
Interleukin 6 (IL-6) is a pleiotropic cytokine which has very important role 
in acute phase reaction48. It plays important role in chronic inflammation, 
fibrogenesis, endothelial dysfunction, and autoimmunity48. Its expression 
is high in autoimmune diseases and inflammatory conditions49. The 
various stimuli such as Toll-like receptor ligands, IL-1, IL-7, TNF-alpha, 
PAF and physical exercise are involved in the release of IL-616. 
2.5.8 Interleukin 7 
 
Interleukin 7 (IL-7) is a potent cytokine which stimulates T-cells in normal 
as well as disease state in T-cell expansion and differentiation. It is 
involved in various autoimmune diseases like inflammatory bowel 
diseases, rheumatoid arthritis and multiple sclerosis50. IL-7 can cause 





2.5.9 Interleukin 8 
 
Interleukin 8 (IL-8) belongs to CXCL family, which is activated by various 
stimuli like TNF-alpha, IL-1β, hypoxia, androgens and estrogens52. It is 
particularly secreted by monocytes, neutrophils, macrophages and 
involved in acute inflammatory responses52. The IL-8 and its receptor is 
involved in gliomagenesis and tumoral angiogenesis53. 
 
2.5.10 Interleukin 9 
 
Interleukin 9 (IL-9) is pro-inflammatory cytokines involved in various 
immune  pathological conditions and inflammatory diseases ranging from 
asthma to parasitic infections54. IL-9 has effect on both mast cells and T-








2.5.11 Interleukin 10 
 
Interleukin 10 (IL-10) is an anti-inflammatory cytokine which decreases 
the activation of T-cells, monocytes and macrophages56. The primary 
function of IL-10 is to inhibit the inflammatory responses56. It is also 
known that overexpression of IL-10 in some tumors and lymphomas can 
promote further tumor development57.  
 
2.5.12 Interleukin 12 
 
Interleukin 12 (IL-12) is a pro-inflammatory cytokine which secreted by 
activated antigen presenting cells such as monophages, dendritic cells 
and macrophages58. It has been found to upregulate TH2-type cytokines. 







2.5.13 Interleukin 13 
 
Interleukin 13 (IL-13) is a pro-inflammatory cytokine which is released by 
T-cells and dendritic cells. IL-13 and IL-4 shares the same IL-4 alpha 
complex receptor and share common biological functions involving signal 
transduction60. It activates mast cell, eosinophil and neutrophil function 
as well as play vital role in allergic airway diseases61. Studies has shown 
IL-13 reduces cardiac injury and heart dysfunction through M2 
polarization62. 
 
2.5.14 Interleukin 15 
 
Interleukin 15 (IL-15) is a pro-inflammatory cytokine which is very unique. 
During inflammation or stress it is neither secreted nor upregulated on 
cell surface. Its expression is dependent on private IL-15R alpha chain63. 





2.5.15 Interleukin 17 
 
Interleukin 17 (IL-17) is recently discovered cytokine that is produced 
exclusively by T-cells and variety of innate cells like macrophages, natural 
killer cells, dendritic cells. It promotes inflammatory responses in 
autoimmune diseases and other various inflammatory diseases64. 
Targeting IL-17 has been important therapeutic strategy in the treatment 
of plaque psoriasis65.  
2.5.16 Eotaxin 
 
Eotaxin is a chemokine which is produced by different cells such as 
macrophages, eosinophils, lymphocytes, endothelial cells, respiratory 
cells, smooth muscle cells, fibroblast and keratinocytes65.  It has been 
reported that eotaxin promotes the vascular smooth muscle cells 
activation and play important role in the cardiovascular disease, 
especially in elderly patients66.  
2.5.17 Granulocyte colony stimulating factors 
 
Granulocyte colony stimulating factor (GMCSF) is a glycoprotein that 
induces survival, proliferation, differentiation and function of neutrophil 
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granulocytes and their precursors67.It is the major cytokine that regulates 
the function of neutrophilic granulocytes. Recombinant GCSF has 
become common in treatment of neutropenia68. It is known that the mice 
model lacking GCSF has chronic neutropenia and granulocytes66. 
2.5.18 Interferon gamma 
 
Interferon gamma (IFN-gamma) is an important cytokine that induces and 
modulates immune responses. It is produced by T-cells and natural killer 
cells (NK)69. It functions through JAK-STAT signalling pathway70. It has 
different functions such as activating innate immune system, 
macrophages, mediating balance between TH1 and TH2 cells, controlling 
cellular proliferation and apoptosis. 
 
2.5.19 Macrophage inflammatory protein alpha 
 
Macrophage inflammatory protein alpha (MIP-1α) is a pro-inflammatory 
chemokine secreted by different cells such as dendritic cells, 
macrophages and lymphocytes72. It plays important role in inflammation 
associated to Rheumatoid arthritics72. MIP-1α is important in the 
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regulation of T-lymphocytes and monocytes. It plays vital role in 
stimulation of other cytokines especially TNF-alpha, IL-1 and IL-6 and the 
degranulation of mast cells, and the initiation of macrophage-derived 
inflammatory responses73. 
2.5.20 Platelet derived Growth factor- BB 
 
Platelet derived Growth factor (PDGF) acts via two receptors PDGFR- 
alpha and PDGFR- beta74. PDGF are important in angiogenesis or 
endothelial progenitor cells and mesenchymal stem cells. Increased level 
of PDGF-BB is found in several diseases such as pulmonary 
hypertension, retinal vascular disease and dermal fibrosis74.  
2.5.21 Regulated  on activation, Normal T-cell Expressed 
and secreted (RANTES) 
RANTES is also called as CCL5, are important chemokine that play role 
in stimulation of natural killer cells, T-cells, monocytes, eiosinophils and 





2.5.22 Monocyte chemoattractant Protein 1  
 
MCP-1 is a important chemokine which is induced by many cells either 
by oxidative stress, cytokines and growth factors77. It is mainly secreted 
by endothelial cells, epithelial, smooth muscle, mesangial cells, 
monocytic and microglial cells77.  MCP-1 are found over expressed in skin 
lesions, tissue fibrosis and systemic sclerosis78. 
2.5.23 Vascular Endothelial Growth factors 
 
VEGF activates tyrosine kinase enzyme by binding to the tyrosine kinase 
receptor thus stimulating intracellular pathways79.  It is released by 
vascular endothelial cells and to some extent to non-endothelial cells79. It 
is involved in the pathogenesis of angiogenesis, tumors, ischemia and 
inflammation79. 
2.5.24 Fibroblast growth factors 
FGF has significant effects on the growth and regeneration of tissues80. 
It is expressed in cells and tissues and found in both vertebrate and 
invertebrate80. It comprises of 22 members and early it was thought to 
promote fibroblast proliferation. Its main funtion is to enhance 
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2.5.25 Granulocyte Macrophage Colony-Stimulating 
Factor 
 
GM-CSF is an important cytokine involved in regulation of macrophage 
numbers and functions81. It is generated by number of cells like  
fibroblasts, osteoblast, smooth muscle and macrophages. Higher levels 
of GM-CSF are found in various complications such as inflammation, 
cancer and autoimmune diseases81.  It activates the monocytes and 
macrophages and also helps in differentiation to other state and involved 






2.5.26 Interferon-γ-Inducible-Protein-10 Interferon 
 
It is also known as CXCL-10 which is released from different cell lines 
such as keratinocytes, leukocytes, eosinophils, monocytes, netrophils 
epithelial cells. It plays major role in cell growth, apoptosis and angiostatic 
effects. It is also important mediator in migration of  T-cells, NK cells and 
monocytes82. 
2.5.27 Macrophage Inflammatory Protein (MIP) 
 
MIP is a inflammatory protein that is sub-divided into two different 
chemokines, MIP alpha protein (MIP-1α) and MIP beta protein (MIP-1β). 
MIP-alpha is secreted form different  cells like moncytes, T lymphocytes, 
B lymphocytes, dendritic cells, basophils, fibroblast83. Similarly MIP-beta 
is also secreted from Monocytes, NK cells, dendritic cells, microglia and 
neutrophils83. It plays major role in migration and activation of monocytes, 
neutophils, eosinophils and basophils83. 
2.6 Microvesicle particles (MVP) and Cytokines 
 
The release of MVP is a important means of intercellular communication 
which is shared by many cell types, mainly they are involved in transfer 
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of cell contents. The released MVP can enter the body fluids and 
potentially travel to other tissues84. MVP are capable of transfering cargos 
loaded from the parent cells to other neigbouring cells or distant tissue 
and play role in inflammatory diseases including cancers, angiogenesis 
and artherosclerosis27,5.The agents carried by MVP depends on the 
parent cell type. In microglial cells, astrocyte-derived ATP induces the 
formation of MVP and cytokine (interlukin-1β), IL-1β found to be present 
in MVP which subsequently efflux in the extracellular environment86. IL-
1β, key initiator of acute inflammatory responses, enhanced by ATP 
stimulation was inhibited by P2X7R antagonist20,30. IL-1β release in the 
microvesicle by ATP stimulation has been studied in time dependent 
manner. The release of IL-1β was found as early after 2 minutes of 
stimulation and the concentration of IL-1β changes with the time37. In one 
of the study it is found that microvesicle shedding is due to activation of 
acid sphingomyelinase enzyme and also IL-1β secretion is dependent on 
aSMase.  MVP shedding and IL-1β release is blocked by aSMase 
inhibitor, imipramine9. The aMAase KO astrocytes have been reported to 
have decreased MVP shedding and IL-1β release, which can be restored  
by addition of P2X7R agonist23. 
Based upon these disparate literature reports and our own laboratory’s 
findings, we hypothesize that the concentrations of cytokines or proteins 
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in the MVP and even shedding of MVP may change in time dependent 
manner. The study of  kinetics of  MVP shedding and generation of 
several other cytokines along with IL-1β could be important study to learn 
more about the role of MVP in different diseases. In this study, we on 
cytokines like tumor necrosis factor (TNF-alpha). As mentioned earlier, 
acid sphingomyelinase inhibitor can block MVP shedding and IL-1β in 
microglial cells and astrocytes31,23. There are very few studies going on 
keratinocyte derived MVP, but it could be very possible that several 
keratinocytes derived MVP could contain different kinds of cytokines. In 
this study, we have hypothesized that keratinocyte derived MVP could 
contain possible cytokines (TNF-alpha) and they could transfer these 
inflammatory cytokines to different parts of the body leading serious 









2.7 Toxic Epidermal Necrolysis 
 
The wide spread use of drugs has increased with advancement in 
research and development in the field of medicine. Along with benefits 
there are considerable morbidities associated with the adverse reactions 
associated to drugs. Toxic Epidermal Necrolysis (TEN) is mainly drug 
induced reaction. It is very rare but severe life-threatening disorder87. It is 
the most severe amongst the epidermolytic adverse cutaneous drug 
reactions. TEN is characterized by keratinocyte cell death that separates 
skin layer at dermal-epidermal junction followed by bullous de-attachment 
and skin sloughing86,87,89.  The cell death and mucous de-attachement 
leads to other symptoms which includes anxiety, high fever, mucosilitis, 
severe pain, asthenia, genitourinary, ocular damage. The underlying 
mechanism of TEN is still unkown, yet it has been reported that the  blister 
formed at the conjuction of dead epidermis and dermis has high levels of 
cytokines like TNF-alpha, IL-12, IL-1889.  Other studies have shown that 
high level of TNF-alpha and IFN- activates the Inducible Nitric Oxide 
Synthase leading to severe conditions90. 
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Though multiple cases of TEN have been reported, the exact mechanism 
for this life-threatening condition is unknown. In 2010, there was a case 
of TEN in a 22 year old young  girl who was absolutely healthy other than 
mild drug hypersentivity reactions to non-steroidal anti-inflammatory 
drugs. She developed a mild allergic reaction with red macules and 
papules on her back, chest and fore-arm after the ingestion of 200mg 
Ibuprufen. Two days after the rashes and allergic reaction in order to self 
-treat, she went to bed tanning therapy with UV (UVA + UVB) light. 
Unfortunately, after 4 hours of UV light exposure she developed itchiness 
and rashes in the skin exposed to UVB.  The next morning skin blister 
formation started with irritation in throat, redness, swolling and vaginal 
abnormalities. Eventually she was admitted to the hospital, the skin 
biopsies and blister from affected area was tested. The presence of high 
level of TNF-alpha in the blister and skin biopsies compared to control 
was very suprising91. The Ultraviolet light causes keratinocyte damage 
leading to cell death and  generation to cytotoxic cytokines in the 
epidermis. It was quite suprising how the TNF-alpha present in the skin 
blister and biopsy reaches the system of the body. At presently, our lab 
is focused in the study of MVP particles, and we have hypothesized that 
these extracellular vesicles could be loaded with exaggerated level of 
cytokines generated due to combination of UV light and drug 
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hypersensitivity reaction and circulate throughout the body causing 
systemic effect described in this incident.  
Figure 3. Clinical photographs of skin biopsy and blister 
formation showing toxic epidermal necrolysis and tumor 








Imipramine is tricyclic antidepressant drug clinically used in the treatment 
of neuropathic pain and major depression92. Four decades ago, 
imipramine was discovered as a potent drug that has ability to inhibit the 
acid sphingomyelinase enzyme92. Acid spinghomyelinase enzyme is a 
known lysosomal enzyme present in lysosomal compartment, which 
translocates from lysosomal region to plasma membrane. aSMase 
enzyme hydrolyses sphingomyelin lipid into ceramide in the plasma 
membrane93. The production of ceramide in the outer plasma membrane 
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activates the intracellular molecules which are involved in transmission of 
various signals92. It is also known that deficiency of aSMase enzyme 
leads to Type A and Type B  II Niemann-Pick diseases (NPD). It is also 
found that stimulation of aSMase enzyme via PAF-R activation increases 
vascular permeability in acute lung injury94. The aSMase KO mouse has 
been created, which mimics many aspects of the human Niemann-Pick 
disease. aSMase KO mouse have been reported to be resistant to 
radiation, stress induced apoptosis like FAS or CD95, ischemia, 
chemotherapy and tumor necrosis factor alpha95,96,97.  
Previous studies have shown that UVC light induces translocation of 
aSMase from lyosomal region to plasma membrane. The stimulation of 
UVC light induces ROS generation which enhances aSMase enzyme 
translocation and PDTC, anti-oxidant inhibited the translocation of 
aSMase enzyme98. This supports the hypothesis that UVC light via ROS 
generation stimulates translocation of the aSMase enzyme, resulting in 
the upregulation of ceramide levels in the plasma membrane. It has been 
found that high level of ceramide mediates UV signals resulting in 
mitochondrial DNA damage94.  
The activation of acid sphingomyelinase enzyme and production of 
ceramide induces extra cellular vesicles particularly MVP in microglial 
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cells. Acid sphingomyelinase pathway through activation of P2X7R is a 
major mechanism involved in MVP generation9. Along with MVP, 
cytokines like TNF-alpha and IL-1β are secreted via activation of P2X7R 
receptor through the acid sphingomyelinase pathway11,96. TNF-alpha and 
IL-1β are two major cytokines that cause apoptosis and inflammation in 
neuronal cells. TNF-alpha and IL-1β induced apoptosis and inflammation 
are correlated with increased levels of ceramides. The suppression of the 
aSMase pathway in glial cells decreased ischemic damage in 
neurons95,86. It is believed that secretion of cytokines in the MVP is a 
major mechanism of release of cytokines from microglial cells. 
Imipramine, acid sphingomyelinase inhibitor, blocks MVP and IL-1β from 
microglial cells and aSMase KO astrocytes11,85.  
 






                   Chapter 3: Materials and Methods 
1.1 Introduction- 
 
In this chapter we will discuss the model systems, materials, procedures 
and analysis performed to acquire the relevant data to answer the 
experimental questions of this study. The model systems used in this 
study are mainly in-vitro cell lines and an in-vivo murine model. 
1.2 Cell culture- 
 
There were three cell lines used in the experiments, spindle- shaped 
HaCaT cell lines, derived from spontaneously immortalized human 
keratinocytes. KB cells were isolated from a patient with a 
nasopharyngeal carcinoma. The cells were later transduced with 
MSCV2.1 retrovirus containing PAF-R (KBP) and KBM cells with control 
MSCV2.1 retrovirus without PAF-R99.  
1.3 Cell growth media and storage condition 
 
Complete media containing Dulbecco’s modified Eagle’s medium (DMEM 
Hyclone, Logan, UT) added with 10% fetal bovine serum (Hyclone, 
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Logan, UT), 100 U penicillin/0.1 mg/ml streptomycin (5ml),and 2mM 
glutamine (5 ml)  was used to grow the three cell lines, HaCaT, KBP and 
KBM. All the cells were kept at 37ºC and 5% C02 in humidified incubator. 
3.4. Cell passage 
Growth media were removed from the culture plates and culture plates 
were washed 3 times with 10 ml of PBS 1X. 0.25% of Trypsin-EDTA 1X 
(for HaCaT) and 0.05% of Trypsin-EDTA 1X (KBP/KBM) was added to 
each plate and incubated for 10 minutes. Then, when cells start to de-
attach from the plate add 8ml of media to each plate to bring the volume 
to 10ml and then cells were triturated. For normal cell passage, 6 drops 
of the cells suspended in media was added to new plate with fresh media 
10 ml. For HaCaT cells 2.5 ml of cells were added to 10 ml of fresh media 
in 10 cm2 plates. 
The cells which needed to be treated were counted before adding to the 
new plates and ensure that equal number of cells are added to each plate. 
The number of days required for the cells to get confluent had crucial role 
to get the consistent results. For consistent results, every time cells were 






1.4 Changing media 
 
To change the media, the old media was removed from the culture plate, 
and the plate was washed thrice with 10ml PBS 1X. Then 10 ml of fresh 




1.5 Cell count 
 
To count the cells, first cells were washed thrice with 10 ml PBS 1X. Then 
procedure of addition of trypsin was followed and then 200µl of cells 
suspended in fresh media were added to 800µl of PBS 1X in 1.5 ml of 
microcentrifuge tubes and total number of cells were counted with 





1.6 Bringing up cells from liquid Nitrogen 
 
The vials after taking out from Liquid Nitrogen, were thawed in hand and 
cells were immediately added to new culture plate containing 10 ml of 
fresh media. The next morning cell were fed and then passage into new 






3ml of Hank’s Balanced Salt Solution and 10mg/ml Bovine serum albumin 
(HBSS+BSA) with desired concentration of treatments reagents were 
added to each plate. Sham culture plates received no treatment and were 
incubated for desired length of time. Vehicle treated cells received 0.1% 
of Ethanol and HBSS+BSA. CPAF treated cells received 3µl of 100µM 
CPAF added to 3 ml of HBSS+BSA to obtain final concentration of 
100nM. PMA treated cells received 3µl of 500µM PMA added to 3 ml of 
HBSS+BSA calculated to final concentration of 500nM. UVB treated cells 
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received 600 J/m2 for 2 minutes with lids off. For the combination 
treatment, CPAF+UVB, 3 µl of 100µM CPAF and 3 ml of HBSS+BSA was 
added and incubated for half an hour in the incubator. After half an hour 
the culture plates were irradiated with 600 J/m₂ of UVB. Then the plates 
were incubated for desired duration of time. For, PMA+UVB, 3µl of 500µM 
of PMA and 3ml of HBSS+BSA were added together and incubated for 
30 minutes. Then 600J/m2 of UVB was irradiated for 2 minutes and 
incubated for required time. For time response study, the samples were 
collected in between 0-4 hours, 4-8 hours and 8-24hours time period. 
After the collection of samples at each time point, the fresh HBSS+BSA 
was added to the plates and incubated for required time period.  
For the dose response study, several doses of CPAF (1nM, 10nM, 50nM, 
100nM, 200nM & 250nM) and UVB (200 J/m2, 400 J/m2 , 600 J/m2, 800 
J/m2, 1000 J/m2) were added according to the calculated volume along 
with 3 ml of HBSS+BSA in each plate and the supernatant was collected 
after 6 hour time point.  
1.8 Inhibitors 
 
After the plates were washed thrice with Hanks Balanced Salt Solution 
(HBSS). Imipramine, an aSMase inhibitor used in the experiments was 
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added to the plate and incubated for 1 hour before the treatment. 3 µl of 
50 mM Imipramine with 3 ml of HBSS +BSA was added to each plate to 
make final concentration of 50µM and incubated for 1 hour before the 
treatment. But for UVB, the inhibitors were added after the UVB treatment 
because imipramine has sunscreen effect which blocks the UVB.  
 
 
1.9 MVP isolation 
 
After the determined incubation time, 2ml of supernatant from the treated 
culture plates were transferred to 2 ml centrifuge tubes and centrifuged 
immediately in microcentrifuge tubes at 2000 x g for 20 minutes at 4ºC. 
Then the supernatant was transferred to new tube and centrifuged at 
20,000 x g for 70 minutes. After the centrifugation that supernatant was 
discarded, and the pellet was re-suspended in 100µl of 1x PBS. The 
samples were analyzed with Nano Sight NS300.  Before analyzing the 
sample, the particles should be diluted according to the threshold of the 






The reading obtained from the Nano Sight NS300 was multiplied by the 
dilution rate and then divided by the cell count. The total MVP count 
normalized with cell number were multiplied by 100,000 cells. The errors 
were calculated for each treatment groups and graphed on GraphPad 
Prism 8 and analyzed with one-way and two-way ANOVA to show 
significance with a 95% confidence interval. 
 
 
1.11 ELISA (Enzyme Linked Immunosorbent Assay) 
 
Human high sensitivity TNF-alpha kit from Thermo Fisher Scientific was 
used to quantify the concentration of TNF-alpha in the supernatant 
isolated after the treatment with 100nM CPAF, 500nM PMA, 600 J/m2 
UVB and combination of CPAF/PMA with UVB. The supernatant for 
ELISA was collected from the same culture plate used to collect 
supernatant for isolation of MVP. The procedure was completed following 
the protocol from the kit. Then the plate was read in micro-plate reader. 
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Standard curve with known concentration of TNF-alpha was used as 





1.12 Cytokine Expression Assay 
 
 HaCaT and KBP cells were treated with 100nM CPAF, 500nM PMA, 600 
J/m2 UVB and combination of CPAF/PMA with UVB, MVP and 
supernatant were extracted in between 4 to 8hours time frame. The total 
protein content was analyzed in both MVP and supernatant with protein 
assay. MVP concentration were measured with NanoSight Instrument. 
Then samples were given to Dr. David Cool to conduct a Bio-plex ProTM 
Human Cytokine 27-plex Assay to analyze MVP contents for human 
cytokine expression. 27 cytokines were analyzed: FGF basic, Eotaxin, G-
CSF, INF-γ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-
12 (P70), IL-13, IL-15, IL-17, IP-10, MCP-1 (MCAF), MIP-1α, MIP-1β, 





C57BL/6EGFP wild type mice were obtained from Indiana University-
Purdue University Indianapolis (IUPUI). Mice were housed together, 
provided with water and food ad libitum in a 12 hours light and dark cycle 
room. The protocol for the experimental use of animals was approved by 
Wright State University, School of Medicine’s Laboratory Animal Care 
and Use Committee (LACUC). 
1.14 Treatment 
 
Mice were injected with ketamine/xylazine, shaved and treated with 100 
µl of 100 nM CPAF and the skin was irradiated with 1000 J/m2 of UVB. 
For the combination treatment, shaved back was treated with 100nM 
CPAF for an hour and then irradiated with 1000 J/m2 of UVB. The mice 
were then placed in the cage for 4hours incubation time period. 
1.15 MVP extraction from Punch Biopsies 
 
After 4hours of incubation time period 5 mm punch biopsies were taken 
from the treated skin on the back and each skin biopsies were individually 
weighed. The skin biopsies were placed in 2ml microcentrifuge tubes and 
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500 µl of 5 mg/ml collagenase dispase made in1:1 H2O and Trypsin-
EDTA (0.5%) no phenol red was added to each tube. The tissue was 
finely chopped in the microcentrifuge tube and digested overnight in the 
shaker at 37ºC. After the overnight digestion, 500 µl of filtered PBS was 
added and then centrifuged at 2000 x g for 20 minutes. Then supernatant 
was transfered to clean microcentrifuge tubes and centrifuged at 20,000 
x g for 10 minutes. Then the supernatant was moved to a clean 
microcentrifuge tube and centrifuged at 20,000 x g for 70 minutes. 
Supernatant was discarded and the pellet was re-suspended in 100µl 
filtered PBS (1X). Samples were stored at -80ºC until analysis. 
1.16 Blood sample collection 
 
At the same time blood was collected from the mice, euthanized in CO₂ 
tank and cervically dislocated. The blood was drawn from the heart of a 
mice with 1ml of 30g BD syringe and collected in the microcentrifuge 
tubes. Blood plasma was isolated by centrifugation at 2000 x g for 20 min 
and the blood plasma (upper clear layer) was isolated pipetted in new 
tube carefully. The MVP was isolated after centrifugation at 2000 x g for 





Mean and significance were determined, and graphs were made using 
GraphPad Prism 8. Data is expressed as mean± standard error. Groups 
were compared using one-way ANOVA. Differences in sample were 
considered significant if the P values were less than 0.05. Notation within 
the figure include P<0.05 (*), P<0.01(**), and P<0.001(***). 




                       Chapter 4: Results 
4.1 In-vitro studies 
 
The first part of our studies was to determine dose response effect of 
various stimuli. It was important to study the dose response curve to 
determine the potential dose that could augment MVP release without 
inducing maximal and/or toxic effects. Previous studies from our group 
have shown that higher fluences of UVB (above 1000 J/m2) are needed 
to induce increased levels of MVP release 2. UVB induced MVP release 
is PAF- dependent2.  We already know UVB and PAF-R activation 
induces MVP release in dose dependent manner. But we are focused to 
study what could be the outcome when we combine these stimuli. The in-
vitro study was done in human epidermal cell lines, HaCaT and PAF-R 
positive cell line KBP cells. 
4.2 HaCaT cells 
 





To determine the appropriate dose for the combination study, a dose 
response curve was highly important. To determine the dose response 
effect of CPAF and UVB on HaCaT cells, various doses of CPAF (1nM, 
10nM, 50nM, 100nM, 200nM, 250nM) and UVB (200 J/m2, 400 J/m2 ,600 
J/m2, 800 J/m2, 1000 J/m2) were used to treat keratinocyte derived 
HaCaT cells and incubated at 37ºC for 6 hours. As shown in Fgure 4a, 
HaCaT cells responded to 50nM, 100nM CPAF with increased level of 
MVP compared with control. There was significant increase in MVP 
release with 200nM of CPAF compared to control. Increased 
concentrations of CPAF induces high level of MVP until 200nM and then 
there was decrease in the level of MVP. These studies suggest that high 
concentration of CPAF may cause cell death leading to decrease in 
release of MVP. In Figure 4b, we investigated the appropriate dose of 
UVB that could be used to obtain a synergistic release of MVP without 
overwhelming the cells.  HaCaT cells treated with 600 J/m2 UVB has no 
significant increase in MVP compared to control. Higher doses of UVB 
(800 J/m2 and 1000 J/m2) has significant increase in MVP release 
compared to control. 
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Figure 4. Dose response study of MVP release from CPAF and 
UVB in HaCaT cells  
a) HaCaT cells were treated with either no treatment or different doses 
of CPAF (1nM, 10nM, 50nM, 100nM, 200nM, 250nM) and incubated for 
6 hours, b) HaCaT cells were treated with either no treatment or 
different doses of UVB (200 J/m2, 400 J/m2, 600 J/m2, 800 J/m2, 1000 
J/m2) then cells were incubated for 6 hours. The data represents mean± 
SE MVP per ml per 100,000 cells (average of n=3). Groups were 






























































































































































considered significant if the P value were less than 0.05. P<0.05 (*), 
P<0.01(**), and P<0.001 (***). 
It has been found early that aSMase induced MVP release and increased 
cytokine release in the MVP23. The inhibition of MVP release and cytokine 
from aSMase KO astrocytes indicates that MVP shedding could be 
important mediator in release of cytokine from glial cells23. Hence MVP 
shedding via aSMase ceramide pathway is considered important lipid 
pathway and studies has shown that it may alter the MVP content via 
control release. Though there are several studies related to MVP release 
and cytokines in the MVP in other cell lines, very little idea about 
keratinocyte derived MVP is known till this date.  
We knew the pattern of release of MVP from dose response study of UVB 
and CPAF, but as outlined earlier MVP and cytokine content in MVP was 
unknown. We investigated cytokine TNF-alpha levels in the supernatant 
isolated at same time from the same culture plate for MVP study. The 
level of TNF-alpha was measured with high sensitivity Human TNF-alpha 
ELISA kit.  
To determine the level of TNF-alpha, HaCaT cells were treated with 
different doses of CPAF (1nM, 10nM, 50nM, 100nM, 200nM, 250nM) and 
UVB (200 J/m2, 400 J/m2, 600 J/m2, 800 J/m2, 1000 J/m2) and culture 
plates were incubated for 6 hours. After 6 hours, the supernatant was 
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collected and stored at -80ºC. The supernatant was collected at the same 
time and from the same plate used to isolate MVP. The concentrations of 
MVP and TNF-alpha were determined from the same culture plate. From 
Figure 5a, it was seen that concentrations of TNF-alpha increases 
significantly with increase in CPAF dose (50nM and 100nM). From Figure 
5b, there was a significant increase in the levels of TNF-alpha release 
with increased doses of UVB which reached maximum concentration at 
400 J/m2 and then slight decreases with higher dose of UVB (600 J/m2, 
800 J/m2, 1000 J/m2). 






























































Figure 5. Dose response effect of CPAF and UVB on TNF-
alpha production 
a) HaCaT cells were treated with either no treatment or different doses 
of CPAF (1nM, 10nM, 50nM, 100nM, 200nM, 250nM) and incubated for 
6 hours, b) HaCaT cells were treated with either no treatment or 
different doses of UVB (200 J/m2, 400 J/m2 ,600 J/m2, 800 J/m2, 1000 
J/m2) then cells were incubated for 6 hours. The supernatant was 
analyzed for cytokine TNF-alpha by TNF-alpha high sensitivity ELISA 
kit. The data represents TNF alpha concentration in pg/ml. Groups were 
compared using one-way ANOVA. Differences in samples were 
considered significant if the P value were less than P<0.001 (***). 
 
 
4.2.2 Effect of combination of CPAF and PMA with UVB 


























































From the dose response studies we sought to combine multiple doses of 
CPAF and UVB and determine the potential dose that augments MVP 
and cytokine levels. HaCaT cells were treated with multiple stimuli 
including different doses of CPAF and UVB. Low dose of CPAF was 
combined with high dose of UVB, high dose of UVB with low dose of 
CPAF, high dose of both UVB and CPAF, low dose of both UVB and 
CPAF and vice-versa. The cells were treated for 6 hours and supernatant 
were collected at a time for both MVP and cytokine analysis. From this 
study we found that 100nM of CPAF and 600 J/m2 of UVB was sub 
optimal dose for potential synergistic effect. From the Figure 6, we 
observed approximately 15 folds increase in MVP concentration in 
combination of CPAF with UVB and 10 folds increase in MVP release 
with combination of PMA and UVB. PMA, Phorbol myristate acetate, a 
protein kinase C activator, which is a known positive control that induces 















































































Figure 6.Combination of low dose of UVB (600 J/m2) and CPAF 
(100nM) induces synergistic increase in MVP release in 
HaCaT cells. 
HaCaT Cells received no treatment, 0.1% Ethanol, CPAF (100nM), PMA 
(500nM), UVB (600 J/m2) or combination of CPAF and PMA with UVB. 
Supernatant were collected after 6 hours. MVP level were analyzed using 
NanoSight NS300. The data represents mean± SE MVP per ml per 
100,000 cells (average of n=3). Groups were compared using one-way 
ANOVA. Differences in samples were considered significant if the P value 





4.2.3 Effect of CPAF and PMA with UVB in TNF-alpha 
production 
 
We found that combining different stimuli increases MVP release, which 
could carry cytokines released after these stimuli. The cytokines are pro-
inflammatory proteins which could cause different inflammatory effects. 
To study this first we need to know if combining different stimuli increases 
the release of TNF-alpha along with MVP.  
The supernatant collected at the same time during MVP isolation were 
stored at -80ºC for analysis of cytokine level.  The level of TNF-alpha was 
analyzed with high sensitivity Human TNF-alpha ELISA kit and 
concentration of TNF-alpha was determined with the standard TNF-alpha 
provided with the kit. From the figure 7, it is observed there is significant 
increase in the level of TNF-alpha in the combination treatment compared 
with CPAF/UVB/PMA alone. 
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Figure 7. Combination of low dose of UVB (600J/m2) and CPAF 
(100nM) induces synergistic increase in TNF-alpha release in 
HaCaT cells 
HaCaT Cells received no treatment, 0.1% Ethanol as vehicle, CPAF 
(100nM), PMA (500nM), UVB (600 J/m2) or combination of CPAF and 
PMA with UVB. Supernatants were collected after 6 hours. TNF-alpha 
levels were analyzed using High Sensitivity TNF-alpha ELISA kit. Groups 
were compared using one-way ANOVA. Differences in samples were 
considered significant if the P value were less than P<0.05 (*), P<0.01(**), 
 59 
 
and P<0.001 (***). “#” denotes comparison with CPAF, “&” denotes 
comparison with PMA and “^” denotes comparison with UVB. 
The high levels of MVP and TNF-alpha in the same supernatant may 
indicate inter-connection between MVP and cytokine. Previous studies 
from our lab had shown low level of cytokines in MVP compared to control 
treatment. It was opposite to what we have hypothesized but the low level 
of cytokine in the MVP could be body’s defense mechanism to protect the 
body from cytokine storm. In this case combining multiple stimuli, the 
exaggerated level of MVP and cytokine in the supernatant could inhibit 
the body’s defense mechanism and cytokine could be loaded in the MVP.  
The increased level of cytokine in the supernatant could be associated 
with the MVP generation. The level of cytokine was measured at 6 hours 
after the cells were stimulated with multiple stressors. The study only 
shows the level of cytokines in the supernatant from 0-6 hours. These 
finding could not be enough to understand about the MVP and its 
association with cytokines within short period of time. We do not know 
about the peak time when stimulated cells release maximum 
concentration of MVP and cytokines and these inflammatory cytokines 
could be present in the MVP. The kinetics of release of MVP was studied 
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with time response experiments. The level of MVP and cytokine in the 




4.2.4 Time response studies of CPAF/PMA and UVB in 
MVP release 
 
The HaCaT cells received no treatment, ethanol (0.1%), CPAF (100nM), 
PMA (500nM), UVB (600 J/m2) and combination of CPAF/PMA with UVB. 
The supernatants were collected at 0-4 hours, time period, fresh 
HBSS+BSA was added to the plates and incubated for another 4 hours. 
The sample were collected from 4 to 8 hours and concentration of MVP 
and TNF-alpha were analyzed. Similarly, after supernatant was collected 
at 8 hours, time point, fresh HBSS+BSA was added to each plate and 
incubated for another 16 hours. The supernatants were thus collected 
from 0-4 hours, 4-8 hours and 8-24 hours.  
From Figure 8, it was observed that there was ~10 folds increase in MVP 
release with combination of CPAF with UVB compared to CPAF or UVB 
alone. The combination of CPAF/PMA with UVB has also resulted in 
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significant increases in the MVP concentrations compared to treatment 
alone. The MVP level is significantly higher in the 4-8hour time frame as 
compared to 0-4 hour and 8-24 hours. There was no significant 
synergistic increase in MVP concentration in between 0-4 hours and 8-
24 hours. These studies suggest that multiple stressors could stimulate 
the cells to produce maximum number of MVP in the 4 to 8hour time 
frame. This could be the time when body experiences the maximum 
amounts of MVP generation along with exaggerated cytokines in the 
MVP.  
 
Figure 8. Time response study of MVP release from 
































































HaCaT cells were treated with either no treatment or CPAF/PMA/UVB 
and combination of CPAF/PMA with UVB. Supernatant was collected at 
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The amount 
of MVP released after combination treatment was significantly higher than 
control and single treatment particularly at 4-8 hours. The data represents 
mean± SE MVP per ml per 100,000 cells (average of n=3). Groups were 
compared using two-way ANOVA. Differences in samples were 
considered significant if the P value were less than 0.05. P<0.05 (*), 
P<0.01(**), and P<0.001 (***). ‘#’ denotes comparison with CPAF, ‘&’ 
denotes comparison with PMA and ‘^’ denotes comparison with UVB. 
4.2.4 Time response studies of CPAF/PMA and UVB on 
TNF-alpha production 
 
The HaCaT cells received no treatment, vehicle (0.1% ethanol), CPAF 
(100nM), PMA (500nM), UVB (600 J/m2) and combination of CPAF and 
PMA with UVB. The supernatants were collected at 0 to 4 hours, fresh 
HBSS+BSA was added to the plates and incubated for another 4 hours. 
The sample were collected from 4 to 8 hours and concentration cytokine 
level of was analyzed. Similarly, after supernatant was collected at 8hour 
time point, fresh HBSS+BSA was added to each plate and incubated for 
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another 16 hours. Thus, the supernatants were collected from 0-4 hours, 
4-8 hours and 8-24 hours and TNF-alpha level was measured at these 
different time points. 
From Figure 9, it was observed that there was a significant increase in 
the TNF-alpha level compared to control in both combination treatment 
and treatment alone. There were no significant differences in levels of 
TNF-alpha at 0 to 4 hours and 4 to 8 hours in both combination and 
treatment alone. The time period between 8 to 24 hours has significantly 
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Figure 9. Time response study of TNF-alpha release from 
CPAF/PMA/UVB alone and Combination of CPAF/PMA with 
UVB. 
HaCaT cells were treated with either no treatment or CPAF/PMA/UVB 
and combination of CPAF/PMA with UVB. Supernatant was collected at 
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The 
concentration of TNF-alpha after combination treatment was significantly 
higher than control and single treatment particularly at 4-8 hours. Groups 
were compared using two-way ANOVA. Differences in samples were 
considered significant if the P value were less than 0.05. P<0.05 (*), 
P<0.01(**), and P<0.001 (***). ‘#’ denotes comparison with CPAF, ‘&’ 
denotes comparison with PMA and ‘^’ denotes comparison with UVB. 
 
4.2.5 Imipramine modulates MVP release in HaCaT cells 
 
Imipramine, an anti-depressant drug, is known to block the release of 
MVP via aSMase lipid pathway100. Previous studies have shown the 
aSMase inhibitor, imipramine can block MVP release and cytokine (IL-
1β) in micro glial cells23. Thus, our next studies were designed to test the 
ability of imipramine to modulate the release of MVP and cytokine TNF-
alpha in our system. HaCaT cells were pre-treated with imipramine 
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(50µM) for an hour or at the same time with CPAF/PMA/UVB treatment. 
From Figure 10, compared to CPAF/UVB/PMA and pre-treatment with 
imipramine partially blocked the treatment induced MVP release. It was 
also found that UVB induced MVP release is blocked with imipramine. In 
UVB, as imipramine blocks UVB and have sunscreen effect, was added 
after UVB treatment. Imipramine treatment partially blocks the UVB 
induced MVP release. 
 
Figure 10. Inhibition of MVP release in HaCaT cells in addition 
of aSMase inhibitors (Imipramine) for CPAF/PMA/UVB 
treatment. 
HaCaT cells were pre-treated with Imipramine (50µM) for an hour before 
the treatment. Then, CPAF (100nM), PMA (500nM) and UVB (600 J/m2) 





































































different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The level of 
MVP was measured with Nano Sight NS300. The data represents mean± 
SE MVP per ml per 100,000 cells (average of n=3). Groups were 
compared using two-way ANOVA. Differences in samples were 
considered significant if the P value were less than 0.05. P<0.05 (*), 
P<0.01(**), and P<0.001 (***). 
From the above study we determined that the aSMase inhibitor 
imipramine partially blocks the release of MVP in treatment alone. As the 
combination of different treatments exaggerated the MVP release, we 
were curious to learn about the effect of imipramine in inhibition of MVP 
release in exaggerated condition. Imipramine has potent sunscreen effect 
and blocks the UVB effect, so imipramine was added after the 
combination treatment with CPAF and PMA. As shown in Figure 11, it 
was found that there were significant differences in MVP release in 
combination treatment with imipramine, particularly during the time period 
of 4-8 hours. Thus. Imipramine blocks the MVP release in exaggerated 




Figure 11. Inhibition of MVP release in HaCaT cells by addition 
of aSMase inhibitors (Imipramine) for combination treatment 
(CPAF and UVB). 
HaCaT cells were treated with imipramine (50µM) after the combination 
treatment. The combination treatment includes CPAF (100nM) and PMA 
(500µM) with UVB (600 J/m2) and the cells were incubated. Supernatant 
were collected at different time intervals, 0-4 hours, 4-8 hours and 8-24 
hours. The level of MVP was measured with Nano Sight NS300. The data 
represents mean± SE MVP per ml per 100,000 cells (average of n=2). 
Groups were compared using two-way ANOVA. Differences in samples 
were considered significant if the P value were less than 0.05. P<0.05 (*), 
P<0.01(**), and P<0.001 (***). # denotes comparison of imipramine 





































































4.2.6 Imipramine modulates TNF-alpha release in HaCaT 
cells 
 
Imipramine blocks the MVP release in treatment alone and multiple 
treatments. From previous studies we found that MVP release and TNF-
alpha in the supernatant increases with multiple treatments. Thus, MVP 
release from various cells could be an important mechanism by which 
cytokine are released. Various studies have shown that imipramine 
blocks cytokine release along with MVP shedding. Our next studies were 
determined to define the effects of imipramine on TNF-alpha secretion. 
HaCaT cells were pre-treated with imipramine (50µM) for an hour or at 
the same time with CPAF/PMA/UVB treatment. From Figure 12, it was 
known that compared to CPAF/UVB/PMA alone, pre-treatment with 
imipramine blunts the effect of treatment induced TNF-alpha release. It 
was also found that UVB induced TNF-alpha release was partially 
blocked with imipramine. In UVB, as imipramine blocks UVB and have 
sunscreen effect, was added after UVB treatment. Imipramine treatment 



































































Figure 12. Inhibition of TNF-alpha release in HaCaT cells in 
addition of aSMase inhibitors (Imipramine) for 
CPAF/PMA/UVB treatment. 
HaCaT cells were pre-treated with imipramine (50µM) for an hour before 
the treatment. Then, CPAF (100nM), PMA (500nM) and UVB (600 J/m2) 
were added and the cells were incubated. Supernatant were collected at 
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The level of 
TNF-alpha was measured with high sensitivity ELISA kit and data 
represents TNF-alpha concentration from three different experiments. 
Groups were compared using two-way ANOVA. Differences in samples 
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were considered significant if the P value were less than 0.05. P<0.05 (*), 
P<0.01(**), and P<0.001 (***). 
 
From the above study we determined that imipramine, an aSMase 
inhibitor, blocks the release of TNF-alpha in treatment alone. Since 
combination of different treatments exaggerated the TNF-alpha release, 
we were curious to learn about the effect of imipramine in inhibition of 
TNF-alpha release in exaggerated condition. Imipramine has potent 
sunscreen effect and blocks the UVB effect, so imipramine was added 
after the combination treatment with CPAF and PMA. From Figure 13, we 
observed that imipramine blunts the effect of CPAF, and PMA induced 












































































     
Figure 13. Inhibition of TNF-alpha release in HaCaT cells by 
addition of aSMase inhibitor (imipramine) in response to 
combination treatment (CPAF/PMA and UVB). 
HaCaT cells were treated with imipramine (50µM) after the combination 
treatment. The combination treatment includes CPAF (100Nm /PMA 
(500nM) with UVB (600 J/m2) and the cells were incubated. Supernatant 
were collected at different time intervals, 0-4 hours, 4-8 hours and 8-24 
hours. The level of TNF-alpha was measured with high sensitivity ELISA 
kit and data represents TNF-alpha concentration from three different 
experiments. Groups were compared using two-way ANOVA. Differences 
in samples were considered significant if the P value were less than 0.05. 
P<0.05 (*), P<0.01(**), and P<0.001 (***). # denotes comparison of 






4.3 KBP cells 
 
4.3.1 Dose response effect of CPAF and UVB in MVP 
release 
 
Previous studies from our group has found that UVB induces MVP 
release in KBP (PAF-R positive cells) yet not in KBM (PAF-R negative 
cells). The release of MVP is thus dependent on PAF-Receptor activation. 
Cells were stimulated with CPAF, PMA and UVB in normal condition. The 
exaggerated condition was not studied before with multiple stimuli. These 
studies were to demonstrate the effect of multiple stimulation in KBP cells. 
To determine the dose response effect of CPAF and UVB on KBP cells, 
various doses of CPAF (1nM, 10nM, 50nM, 100nM, 200nM, 250nM) and 
UVB (200 J/m2, 400 J/m2 , 600 J/m2, 800 J/m2, 1000 J/m2) were used to 
treat keratinocyte derived KBP cells and incubated at 37ºC for 6 hours. 
First, we determined dose response effect of different stimulus and 
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figured out potential dose which has maximum effect on MVP release in 
PAF-receptor positive cell line KBP. From Figure 14a, it was observed 
that 50nM and 100nM of CPAF resulted in increased levels of MVP 
release than control while 200nM of CPAF has significant increase in 
MVP release compared to control. It was also observed that 250nM of 
CPAF induced decreased level of MVP compared to other doses. 
Similarly, from Figure 14b using KBP cells, 600 J/m2 has minimum effect 
in MVP generation compared with control treatment. While increase in 
dose of UVB, (800 J/m2 & 1000 J/m2) there is significant increase in MVP 

















































































































   






















Figure 14. Dose response study of CPAF and UVB in KBP 
cells. 
a) KBP cells were treated with either no treatment or different doses of 
CPAF (1nM, 10nM, 50nM, 100nM, 200nM, 250nM) and incubated for 6 
hours, b) KBP cells were treated with either no treatment or different 
doses of UVB (200 J/m2, 400 J/m2, 600 J/m2, 800 J/m2, 1000 J/m2) then 
cells were incubated for 6 hours. The data represents mean ± SE MVP 





one-way ANOVA. Differences in samples were considered significant if 
the P value were less than 0.05. P<0.05 (*), P<0.01(**), and P<0.001 
(***). ns denotes no significant. 
 
4.3.2 Dose response effects of CPAF and UVB on TNF-
alpha generation 
 
The next studies were designed to determine the dose response effect of 
CPAF and PMA on TNF-alpha production. To determine the level of TNF-
alpha, KBP cells were treated with different doses of CPAF (1nM, 10nM, 
50nM, 100nM, 200nM, 250nM) and UVB (200 J/m2, 400 J/m2, 600 J/m2, 
800 J/m2, 1000 J/m2) and culture plates were incubated for 6 hours. After 
6 hours, the supernatant was collected and stored at -80ºC. The 
supernatants were collected at the same time and from the same plate 
used to isolate MVP. The concentration of MVP level and TNF-alpha was 
determined from the same culture plate. From the figure 15a, it was 
known that level of TNF-alpha increases significantly with increased 
CPAF doses. The high concentration of CPAF decreases the level of 
TNF-alpha, indicates MVP release could be potential mediator of release 
of cytokines. Similarly, in the UVB irradiated culture plates there is 
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significant increases in the levels of TNF-alpha until 400 J/m2 of UVB and 
















































































































Figure 15. Dose response effect of CPAF and UVB on TNF-
alpha production. 
a) KBP cells were treated with either no treatment or different doses of 
CPAF (1nm, 10nm, 50nm, 100nm, 200nm, 250nm) and incubated for 6 
hours, b) KBP cells were treated with either no treatment or different 
doses of UVB (200 J/m2, 400 J/m2 , 600 J/m2, 800 J/m2, 1000 J/m2) then 
cells were incubated for 6 hours. The supernatant was analyzed for 
cytokine (TNF-alpha) by TNF-alpha high sensitivity ELISA kit. Data 
represents sample from three different experiments. Groups were 
compared using one-way ANOVA. Differences in samples were 
considered significant if the P value were less than 0.05. P<0.05 (*), 
P<0.01(**), and P<0.001 (***). 
 
From our previous studies it was confirmed that MVP release is PAF-R 
dependent. The studies were done in PAF-R positive and PAF-R negative 
cell lines, KBP and KBM cells. The cells were stimulated with CPAF and 
UVB alone. There were no studies conducted testing multiple treatments 
to define potential additive/synergistic effects. The KBP and KBM cells, 
stimulated with multiple stimuli were tested in the next studies. Both KBP 
and KBM were treated with CPAF (100nM), PMA (500nM), UVB (600 
J/m2) and combination with CPAF/PMA with UVB. The culture plates 
 78 
 
were incubated for 6 hours. The supernatants were collected and MVP 
isolated were analyzed with Nano Sight NS300. It was observed that 
there was significant difference in the MVP level in between KBP and 
KBM cells in response to CPAF alone and combination of CPAF and UVB 
(figure 16). There was no significant difference in PMA treated cells 
neither in PMA treatment alone nor in combination treatment. PMA 






























































Figure 16. MVP release in cells that express PAF-R (KBP) and 
cells that do not express PAF-R (KBM). 
KBP and KBM cells were treated with no treatment, vehicle (0.1% 
ethanol), CPAF (100nM), PMA (500nM), UVB (600 J/m2) and 
combination with CPAF/PMA with UVB. The cells were incubated for 6 
hours and supernatants were collected for MVP isolation. MVP level were 
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measured with Nano Sight NS300. The data represents mean± SE MVP 
per ml per 100,000 cells (average of n=3). Groups were compared using 
one-way ANOVA. Differences in samples were considered significant if 




4.3.3 Time response effects of CPAF and UVB on MVP 
release 
 
From the above studies we observed that release of MVP is PAF- 
dependent in both treatments alone and combinations of different stimuli. 
We further investigated the time response effects in KBP cells with CPAF 
and UVB in order to define the kinetics of MVP in KBP cells. The KBP 
cells received no treatment, vehicle (0.1%), CPAF (100nM), PMA 
(500nM), UVB (600 J/m2) and combination of CPAF/PMA with UVB. The 
supernatants were collected at 0-4 hours, fresh HBSS+BSA was added 
to the plates and incubated for another 4 hours. The sample was collected 
from 4 to 8 hours and concentration of MVP and cytokine level of was 
analyzed. Similarly, after supernatant was collected at 8hours time point, 
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fresh HBSS+BSA was added to each plate and incubated for another 16 
hours. The supernatants were collected from 0-4 hours, 4-8 hours and 8-
24 hours.  
As shown in Figure 19, we observed that there is an increase in particle 
release with various treatments compared to control. The combination of 
CPAF/PMA with UVB resulted in a significant increase in the MVP 
concentration compared to treatment alone. The MVP level is significantly 
higher in 4-8hour time compared to 0-4 hour and 8-24 hour. MVP 
concentration decreases significantly in 8-24hour time period than other 
time period.  There was no significant synergistic increase in MVP 
concentration in between 0-4 hours and 8-24 hours. The multiple 
stressors could stimulate the cells to produce maximum number of MVP 
in 4-8hours time point. This could be the time when body experience 
maximum number of MVP generation along with exaggerated cytokines 




Figure 17. Time response study of CPAF/PMA/UVB alone and 
Combination of CPAF/PMA with UVB in KBP cells. 
KBP cells were treated with either no treatment or CPAF/PMA/UVB and 
combination of CPAF/PMA with UVB. Supernatants were collected at 
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The 
concentration of TNF-alpha after combination treatment was significantly 
higher than control and single treatment particularly at 4-8 hours. The 
data represents mean± SE MVP per ml per 100,000 cells (average of 
n=3). Groups were compared using two-way ANOVA. Differences in 
samples were considered significant if the P value were less than 0.05. 
P<0.05 (*), P<0.01(**), and P<0.001 (***). # denotes comparison with 































































4.3.4 Time response effects of CPAF and UVB on TNF-
alpha release 
 
The supernatant collected at the same time from the same culture plates 
along with MVP isolation were stored at -80ºC. The cytokine TNF-alpha 
was measured with high sensitivity human TNF-alpha kit.  From the figure 
18, it was observed that there was significant increase in the TNF-alpha 
level compared to control in both combination treatment and treatment 
alone. The level of TNF-alpha is significantly increased in combination 
treatment compared to treatment alone. There is no significant difference 
in level of TNF-alpha at 0-4 hours and 4-8 hours in both combination and 
treatment alone. The time period between 8-24 hours has significantly 




































































Figure 18. Time response study of CPAF/PMA/UVB alone and 
Combination of CPAF/PMA with UVB. 
KBP cells were treated with either no treatment or CPAF/PMA/UVB and 
combination of CPAF/PMA with UVB. Supernatant was collected at 
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The 
concentration of TNF-alpha after combination treatment was significantly 
higher than control and single treatment particularly at 4-8 hours. Data 
represents sample from three different experiments. Groups were 
compared using two-way ANOVA. Differences in samples were 
considered significant if the P value were less than 0.05. P<0.05 (*), 
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P<0.01(**), and P<0.001 (***). # denotes comparison with CPAF, & 
denotes comparison with PMA and ^ denotes comparison with UVB. 
 
 
4.3.5 Imipramine modulates MVP release in KBP cells 
 
Imipramine is an anti-depressant drug known to block MVP release via 
inhibition of aSMase enzyme. KBP cells were pre-treated with imipramine 
(50µM) for an hour or at the same time with CPAF/PMA/UVB treatment. 
Compared to CPAF/UVB/PMA alone, pre-treatment with imipramine 
significantly blocked the treatment induced MVP release (Figure 19). It 
was also found that UVB induced MVP release is blocked with 
Imipramine. In UVB, as imipramine blocks UVB and have sunscreen 









































































Figure 19. Inhibition of MVP release in KBP cells in addition of 
aSMase inhibitors (Imipramine) for CPAF/PMA/UVB 
treatment. 
KBP cells were pre-treated with imipramine (50µm) for an hour before the 
treatment. Then, CPAF (100nM), PMA (500nM) and UVB (600 J/m2) were 
added and the cells were incubated. Supernatants were collected at 
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The level of 
MVP was measured with Nano Sight NS300. The data represents mean± 
SE MVP per ml per 100,000 cells (average of n=3). Groups were 
compared using two-way ANOVA. Differences in samples were 
considered significant if the P value were less than 0.05. P<0.05 (*), 
P<0.01(**), and P<0.001 (***). 
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From the above study we investigated that imipramine, aSMase inhibitor 
blocks the release of MVP in treatment alone. The combination of 
different treatments exaggerated the MVP release, we were curious to 
learn about the effect of imipramine in inhibition of MVP release in 
exaggerated condition. There was significant reduction in MVP release in 
combination treatment with imipramine. Imipramine blocks the MVP 



















































































Figure 20. Inhibition of MVP release in KBP cells in addition of 
aSMase inhibitors (Imipramine) for combination treatment 
(CPAF/PMA and UVB). 
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KBP cells were treated with imipramine (50µM) after the combination 
treatment. The combination treatment includes CPAF (100nM), PMA 
(500Nm) and UVB (600 J/m2) and the cells were incubated. Supernatant 
were collected at different time intervals, 0-4 hours, 4-8 hours and 8-24 
hours. The level of MVP was measured with Nano Sight NS300. The data 
represents mean ± SE MVP per ml per 100,000 cells (average of n=3). 
Groups were compared using two-way ANOVA. Differences in samples 
were considered significant if the P value were less than 0.05. P<0.05 (*), 
P<0.01(**), and P<0.001 (***). # represents comparison of imipramine 
treatment with CPAF and PMA. 
 
4.3.5 Imipramine modulates TNF-alpha release in KBP 
cells 
 
Imipramine blocks the MVP release in treatment alone and in response 
to multiple combined treatments. The next studies were designed to 
determine the effects of imipramine on TNF-alpha generation in 
stimulated conditions. KBP cells were pre-treated with imipramine (50µM) 
for an hour or at the same time with CPAF/PMA/UVB treatment. The 
supernatants were collected at the same time from the same culture 
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plates along with MVP isolation. Compared to CPAF/UVB/PMA alone, 
pre-treatment with imipramine blunts the effect of treatment induced TNF-
alpha release (Figure 21). In UVB, as imipramine blocks UVB and have 
sunscreen effect, was added after UVB treatment. From Figure 22, we 
observed that imipramine blunts the effect of combination treatment 
(CPAF/PMA with UVB) induced TNF-alpha release. 
 
Figure 21. Inhibition of TNF-alpha release in KBP cells by 
addition of aSMase inhibitor (Imipramine) for CPAF/PMA/UVB 
treatment. 
KBP cells were pre-treated with imipramine (50µM) for an hour before the 
treatment. Then, CPAF (100nM), PMA (500nM) and UVB (600 J/m2) were 
added and the cells were incubated. Supernatant were collected at 
different time intervals, 0-4 hours, 4-8 hours and 8-24 hours. The level of 
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represents concentration of TNF-alpha from three different experiment 
(average of n=3). Groups were compared using two-way ANOVA. 
Differences in samples were considered significant if the P value was less 



















































































Figure 22. Inhibition of TNF-alpha release in KBP cells by 
addition of aSMase inhibitor imipramine for combination 
treatments (CPAF/PMA and UVB). 
KBP cells were treated with imipramine (50µM) after the combination 
treatment. The combination treatment includes CPAF (100nM), PMA 
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(500nM) and UVB (600 J/m2) and the cells were incubated. Supernatants 
were collected at different time intervals, 0-4 hours, 4-8 hours and 8-24 
hours. The level of TNF-alpha was measured with TNF-alpha high 
sensitivity ELISA kit. The data represents concentration of TNF-alpha 
from three different experiment (average of n=3). Groups were compared 
using two-way ANOVA. Differences in samples were considered 
significant if the P value were less than 0.05. P<0.05 (*), P<0.01(**), and 





Our next studies were designed to show that in living models the possible 
induction of synergistic MVP release in response to the combination of 
different stimuli. C57BL/6 wild type mice were used in the studies. The 
mice were pre- injected intra-peritoneal with ketamine/xylazine, shaved 
and treated with no treatment, vehicle, 100 µl CPAF (100nM), UVB (600 
J/m2) and combination of 100µl CPAF (100nM) and UVB (600 J/m2). The 
mice were euthanized after 4hours and skin samples were collected by 5 
mm punch biopsies. At the same time blood was collected and blood 
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plasma was isolated.  Skin biopsy was digested in collagenase dispase 
overnight and MVP was isolated by centrifugation (2000 x g for 20 
minutes in 4ºC and 20,000 x g for 70 minutes in 4 ºC) and MVP 
concentration was analyzed by Nano Sight NS300.  
The blood plasma was isolated by centrifugation at 2500 x g for 15 
minutes and the clear white part of the isolated from the blood was 
separated carefully. The separated supernatant was centrifuged at 2000 
x g for another 20 minutes to remove cellular debris and blood. MVP was 
isolated by centrifugation (2000 x g for 20 minutes in 4 ºC and 20,000 x g 
for 70 minutes in 4 ºC) and MVP concentration was analyzed by Nano 
Sight NS300. From Figure 23, we observed that there was a significant 
increase in particle release with combination treatment compared to 





































            
Figure 23. MVP release in mice skin increases after 
combination treatment with CPAF and UVB. 
Wild type mice were injected with ketamine xylazine shaved and treated 
with no treatment, 100µl of ethanol (100%) as vehicle, 100µl CPAF 
(100nM), UVB (1000 J/m²) and the combination. For combination, mice 
back were treated with 100µl of 100nM CPAF and after an hour the back 
was irradiated with 1000 J/m² of UVB. After 4 hours skin biopsy sample 
were collected. MVP concentration was read with Nano Sight NS300. The 
data represents mean± SE MVP per ml per gram tissue (average of n=2). 
Groups were compared using one-way ANOVA. Differences in samples 
were considered significant if the P- value was less than 0.05. P<0.05 (*), 
P<0.01(**), and P<0.001 (***). # & ^ represent comparison with CPAF 









































Figure 24. MVP release in murine blood increases after 
combination treatment with CPAF and UVB. 
Wild type mice were injected with ketamine xylazine shaved and treated 
with no treatment, 100µl of ethanol (100%) as vehicle, 100µl CPAF 
(100nM), UVB (1000 J/m²) and combination. For combination, mice back 
were treated with 100µl of 100nM CPAF and after an hour the back was 
irradiated with 1000 J/m² of UVB. After 4 hours Blood sample were 
collected. MVP concentration was read with Nano Sight NS300. The data 
represents mean± SE MVP per ml of blood plasma (average of n=2). 
Groups were compared using one-way ANOVA. Differences in samples 
were considered significant if the P value was less than 0.05. P<0.05 (*), 
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P<0.01(**), and P<0.001 (***). # & ^ represent comparison with CPAF 
and UVB respectively. 
 
 
4.5 MVP Cytokines Levels 
 
Our studies demonstrated that stimulation of HaCaT and KBP cells with 
combined stimuli resulted in increased levels of MVP and TNF-alpha in 
the supernatants. Thus, multiple stimuli can synergize with each other 
and induce the cells to produce high levels of MVP and inflammatory 
cytokines. The next studies were designed to test if MVP derived from the 
multiple stimuli contained biologically active cytokines. Keratinocytes 
derived MVP samples, treated with various stimulus alone/combined 
were analyzed by Dr. David Cool for the expression of 27 human 
cytokines, chemokines and growth factors listed previously. We were 
surprised with the result, as shown in Figure 25, that keratinocyte derived 
MVP had more Interlukin-1 receptor antagonist. As mentioned earlier, IL-
1ra has anti-inflammatory effects which are unique. Skin keratinocytes, 




               
                                                      
 
Figure 25. Concentration of IL-1Ra in MVP and supernatant 
treated with CPAF/PMA/UVB alone and combination of 
CPAF/PMA with UVB. 
a) HaCaT cells were treated with CPAF (100nM), PMA (500nM) and UVB 
(600 J/m2) and combination of CPAF/PMA with UVB. The supernatants 







































































































the supernatant and stored at -80ºC for analysis of 27 different cytokines, 
chemokines and growth factors. b) HaCaT cells were treated with CPAF 
(100nM), PMA (500nM) and UVB (600 J/m2) and combination of 
CPAF/PMA with UVB. The supernatants were collected during 4-8 hours 
of time period. Supernatant was isolated and stored at -80ºC for analysis 
of 27 different cytokines, chemokines and growth factors.  Both 
supernatant and MVP were analyzed at the same time. Data is 
represented pg/MVP count.  
There was another surprising finding, along with HaCaT cells, the PAF-
R-positive epidermoid cell line KBP was treated with same dose of 
various treatments, but there was no IL-1ra found in either MVP or 
supernatants. This could be due to the reason that only keratinocytes 
produce large number of anti-inflammatory cytokines to protect the body. 
In one of the previous studies, it was found that there was decreased level 
of IL-1Ra in a lupus patient in response to UVB treatment. It was believed 
that reduction of IL-1ra in response to UVB was contributing factor to pro-
inflammatory condition, leading to phototoxicity102  
From Figure 25, we observed there was increased levels of IL-1ra in 
response to UVB treatment in normal keratinocyte derived skin cells, 
(HaCaT). This may be a  protective effect in normal conditions with less 
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sensitizing stimuli, whereas in exaggerated conditions with combination 
treatment MVP do not contain IL-1ra. This could be possible mechanism 
which exploration could provide further insights about how the defense 
mechanism of the body is diminished in exaggerated conditions leading 
to local and systemic inflammatory responses. 
 
  
Table 1. Cytokine, Chemokine and growth factors expressed 
in MVP and supernatant isolated from HaCaT cells that 
received either no treatment, vehicle, CPAF (100nM), PMA 
(500nM), UVB (600 J/m²) and combination of UVB and 
CPAF/PMA. 
The cytokines not listed here were below the detection threshold both in 
MVP and supernatant. INF-g, MCP-1, Rantes, TNF-alpha and human 
VEFG were not present in MVP but few treatments contained these 
cytokines in supernatant. The data represented are average of three 
different samples (n=3).  Data is represented in pg/MVP count and pg/ml 
for supernatant.  
 
No Treatment Vehicle CPAF PMA UVB CPAF+UVBPMA+UVB No Treatment Vehicle CPAF PMA UVB CPAF+UVBPMA+UVB
IL-1ra 3.71628866 11.546 3.5486 4.5486 5.5486 6.5486 7.5486 463.335 1213.9 916.09 1159.4 929.2 766.0067 677.2967
IL-2 0.013149318 0.0111 0.0062 0.0058 0.0129 0.00449 0.0074979 0.205 0.27 0.2833 0.2433 0.84 0.493333 0.406667
IL-5 0.052095111 0.0411 0.0233 0.0283 0.0294 0.01536 0.0227864 0.97 0.68 0.82 0.9033 1.07 0.813333 0.81
IL-8 0.009377049 0.1464 3.6393 17.136 0.0973 0.52036 0.2639745 13.645 78.36 54.737 271.76 148.44 129.5367 220.8567
IL-15 0.456172265 0.3931 0.1475 0.2205 0.2231 0.11201 0.1756152 2.42 4.895 4.5 6.4067 5.1933 3.183333 2.736667
INF-g OOR< OOR< OOR< OOR< OOR< OOR< OOR< 6.31 15.805 10.903 13.613 6.5633 5.256667 5.51
MCP 1 OOR< OOR< OOR< OOR< OOR< OOR< OOR< 12.985 26.22 16.93 14.277 10.91 7.59 6.823333
Rantes OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< 13.743 11.1 OOR< OOR< OOR<
TNF-alpha OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< 66.427 30.80333 27.63







Table 2. Cytokine, Chemokine and growth factors expressed 
in MVP and supernatant isolated from KBP cells that received 
either no treatment, vehicle, CPAF (100nM), PMA (500nM), 
UVB (600 J/m²) and combination of UVB and CPAF/PMA. 
The cytokines not listed here were below the detection threshold both in 
MVP and supernatant. INF-g, MCP-1, Rantes, TNF-alpha and human 
VEFG were not present in MVP but few treatments contained these 
cytokines in supernatant. The data represented are average of three 
different samples (n=3).  Data is represented in pg/MVP count and pg/ml 
for supernatant.                         
 
 
No Treatment Vehicle CPAF PMA UVB CPAF+UVBPMA+UVB No Treatment Vehicle CPAF PMA UVB CPAF+UVBPMA+UVB
IL-1ra OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR<
IL-2 0.004193548 0.0061 0.005 0.0111 0.0031 0.00414 0.0030777 0.33 0.195 0.8467 1.27 0.2033 0.82 1.476667
IL-5 0.017593196 0.0278 0.0118 0.0229 0.0184 0.00907 0.0114413 2.37 0.97 1.1433 1 0.7567 0.916667 0.746667
IL-8 0.009377049 0.1464 3.6393 17.136 0.0973 0.52036 0.2639745 9.5 15.135 262.79 302.51 22.437 24.85 87.28333
IL-15 0.09650386 0.1501 0.0526 0.1025 0.1305 0.04484 0.0828165 16.69 5.32 3.7733 4.1367 4.4933 3.9 3.806667
INF-g OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR<
MCP 1 OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR<
Rantes OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR< OOR<
TNF-alpha OOR< OOR< 43.605 59.983 OOR< 40.94 22.855 OOR< OOR< 97.867 151.52 OOR< OOR< OOR<










Ultraviolet B Radiation is a very common environmental stressor which 
results in both local and systemic effects. The mechanism involved in a 
systemic effect caused by Ultraviolet Radiation is still unknown, though 
murine models have demonstrated involvement of PAF. Previous studies 
from our lab has already demonstrated that exposure of different 
keratinocyte-derived cell lines, murine models and human ex-vivo skin to 
ultraviolet B Radiation generates MVP2. The shedding of MVP from 
different cell lines like microglial cells, astrocytes, and cancer cell lines 
are believed to be involved in cellular responses. It is also thought that 
shedding of MVP could be important mechanism in the release of 
cytokines. Unfortunately, little is known about MVP generation and pro-
inflammatory cytokines associated with MVP shedding in keratinocytes. 
The previous experiments from our lab have shown that treatment of the 
keratinocyte-derived cell line HaCaT, with UVB, PAF agonist CPAF and 
burn injury resulted in very few cytokines, chemokines and growth factors 
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in MVP compared to control treatment. We believe that this might be 
protective mechanism body to avoid cytokine storm in the system.  
It is unknown how UVB, which is only absorbed by the surface of the skin 
exerts systemic effects. The human body has the capacity to defense any 
infections, environmental stressors or chemical toxicities in normal 
conditions. We hypothesized that in normal stimulated conditions, the 
host might may exert defenses to protect against potential cytokine 
storms in the system. This might be the reason we observed less 
cytokines in the MVP compared to control. But there are some conditions 
which these natural defenses could be overridden (for example the case 
of Toxic Epidermal Necrolysis reported due to drug sensitivity + tanning 
bed treatment1). Along with recreational tanning bed therapy, the 
exposure of  UV radiation to human skin are sometimes used to self-treat 
various skin conditions. The mechanism behind progession of toxic 
epidermal necrolysis with tanning bed radiation has not been studied.  
Progression of toxic epidermal necrolysis after tanning bed exposure 
where different stressors may knowingly or unknowingly combine with 
each other to cause exaggerated conditions could be an important clinical 
issue and MVP release could be involved in this process. Does the body 
exert the same defense mechanism in multiple as well as in normal 
stimulated condition? The present  studies were designed explore the 
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effects of the combination of different stressors on MVP generation and 
cytokine release at the same time. 
For in vitro studies, human keratinocyte-derived cell line HaCaT and 
epidermoid cell line KBP with PAF receptor, were treated with UVB alone, 
CPAF alone, PMA alone and combination of UVB with CPAF/PMA. The 
samples were collected in different time periods, 0-4 hours/ 4-8 hours/ 8-
24 hours with change in fresh solution each time after the collection of 
samples. MVP were isolated and analyzed with Nano Sight NS300. At 
the same time samples were analyzed for cytokine (TNF-alpha) 
expression. These studies demonstrated synergistic increase in MVP 
generation along with TNF-alpha in the supernatant with combination 
treatment in human keratinocyte HaCaT and KBP in-vitro. 
Further there were several previously reported studies which 
demonstrated that MVP generation is dependent in aSMase pathway9. 
Moreover, cytokines like IL-1β and TNF-alpha in microglial cells and 
astrocytes were dependent on the aSMase pathway11,96. We found that 
there was synergistic increase in MVP and cytokine release from human 
keratinocytes and epidermoid cells. Our next studies were designed to 
test if MVP and cytokine generation are interconnected with each other. 
Using imipramine, an aSMase inhibitor, we found that imipramine partially 
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blocked both MVP and cytokine release in both treatments alone and 
combination treatment. Imipramine has potential to block the MVP and 
TNF-alpha in exaggerated condition. Since imipramine has potential to 
block both MVP and TNF-alpha even in exaggerated condition, this 
shows that imipramine could be a potential treatment strategy for blocking 
MVP and cytokines like TNF-alpha. It also suggest that MVP could be at 
least partially involved in the release of cytokines. 
We also investigated whether living models like mice respond to 
combination treatments similarly to human keratinocytes and epidermoid 
cell line. We treated the backs of wild type mice with no treatment, CPAF 
alone, UVB alone and combination with CPAF and UVB. After 4 hours, 
skin biopsies and blood sample were harvested, MVP isolated and 
analyzed with Nano Sight NS300. As expected, there was synergistic 
increase in MVP release in skin sample and blood sample. This supports 
our hypothesis that combination of two different stressors, like UVB and 
CPAF could result exaggerated MVP generation and exaggerated 
release of MVP could be involved in pathological mechanisms of skin 
damage resulting in severe systemic complications. 
MVP are extra cellular vesicles potentially involved in cellular 
communication. They transfer bioactive contents from parent cells of 
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origin to different parts of the body leading to various systemic effect in 
the body. UVB irradiated human keratinocytes release various cytokines, 
PAF agonists, COX-2 and many other bioactive substances. We expect 
that the stimulation of cells with combination of different stressors inhibit 
the defense mechanism of body and MVP could be loaded with 
exaggerated level of cytokines. 
Surprisingly, measurement of cytokines contained in MVP did not meet 
our hypothesis. We hypothesized that MVP may contain inflammatory 
cytokines and transfer the cytokines to other parts of the body leading to 
systemic inflammatory responses. The result was opposite to what we 
expect, in that MVP expressed low levels of cytokines except for the anti-
inflammatory cytokines IL-1ra. That irradiation with ultraviolet B Radiation 
in normal keratinocytes produced more IL-1ra in both MVP and 
supernatant was quite interesting. Previous studies showed that 
irradiation of UVB in Polymorphic Light Eruption resulted less in IL-1ra 
than in controls101. The decrease in IL-1ra cytokine could contribute in 
generation of inflammatory photosensitivity disorders. We believe that 
increased levels of IL-1ra in UVB treatment but not in combination of UVB 
and CPAF/PMA could have potential importance. In exaggerated 
conditions with combination treatment, the release the anti-inflammatory 
cytokine IL-1ra could be blocked that could result in imbalance between 
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pro- inflammatory cytokines and down regulating responses. This could 
ultimately result in pro-inflammatory responses. Previously we reported 
that in the patient with toxic epidermal necrolysis associated with tanning 
bed use had higher level of TNF-alpha in the skin biopsy and body fluids1, 
MVP could have carried higher level of cytokines and resulted in systemic 
effect. The result from our studies has shown that there was no TNF-
alpha in the MVP and increase in IL-1ra in MVP treated with UVB but not 
in exaggerated condition with combination treatment. It could be possible 
that in UVB irradiation in normal condition has protective effect with 
increased level of anti-inflammatory cytokines. But in the case of 
combination of UVB with disease or stressed state of cells could block 
the protective effect of UVB, leading to a chronic inflammatory state.  
 5.2 Limitation and Future studies 
 
An important limitation in these studies is that our original multiplex 
cytokine analysis has potential flaws as most values were below the limit 
of detection.  Hence, cytokine analysis could be further investigated.  
Another limitation is that the majority of experiments were conducted in 
cell lines in vitro.  That imipramine did not fully block both MVP and TNF-
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alpha release suggest that the role of MVP in the release of this cytokine 
is more complex than originally hypothesized.    
The pilot in vivo studies in mice demonstrated increase levels of MVP in 
skin biopsy and blood plasma with combination treatment.  Further 
studies could be done to measure cytokine expression and inflammatory 
responses in murine models, to include using PAF-R and/or aSMase 




The data from these experiments strongly support that the combination 
of different stressors induces synergistic increase in MVP release along 
with cytokine TNF-alpha in in-vitro studies. Both MVP and cytokine TNF-
alpha release seem to be at least partially aSMase enzyme pathway 
dependent. Imipramine, aSMase inhibitor blocked MVP and cytokine 
significantly, hence imipramine could potentially have clinical 
significance. MVP release was time dependent, and these studies show 
that the content carried by MVP could be different in a time-dependent 
manner and could have different responses. This study shows that MVP 
could be involved in pathophysiological mechanisms and cytokines 
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carried by these subcellular particles could be involved in pathologies, 
especially photosensitivity disorders. The mechanism of cytokine and 
MVP and clinical implication of imipramine should be further investigated. 
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